DDInter1186 DDInter1376
Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinary tract antiseptic has also been investigated. Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Methylene blue {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ritodrine
Methylene blue {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levosalbutamol
Methylene blue {u} may lead to a major life threatening interaction when taken with {v} Phentermine
Methylene blue {u} may lead to a major life threatening interaction when taken with {v} Valbenazine
Methylene blue {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Tetryzoline
Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Methylene blue may lead to a major life threatening interaction when taken with Phentermine
Methylene blue may lead to a major life threatening interaction when taken with Valbenazine
Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline and Methylene blue may lead to a major life threatening interaction when taken with Tetryzoline